Associated Papers
Phylogenetic analysis of paired breast carcinomas identifies genetic events associated with clonal recurrence and invasive progression.
Kader T et al.
The Journal of Pathology, 2026
Genomic landscape of clinically acquired resistance alterations in patients treated with KRASG12C inhibitors.
Riedl JM et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology, 2025
The Clinicopathological Correlation of KRAS Mutation and PTEN Expression Status in Primary and Metastatic Colorectal Carcinoma.
Hassan RT et al.
Cureus, 2024
Beyond Structural Bioinformatics for Genomics with Dynamics Characterization of an Expanded KRAS Mutational Landscape.
Ratnasinghe BD et al.
Biorxiv : the Preprint Server for Biology, 2023
Beyond structural bioinformatics for genomics with dynamics characterization of an expanded KRAS mutational landscape.
Ratnasinghe BD et al.
Computational and Structural Biotechnology Journal, 2023
A saturation mutagenesis screen uncovers resistant and sensitizing secondary KRAS mutations to clinical KRASG12C inhibitors.
Feng S et al.
Proceedings of the National Academy of Sciences of the United States of America, 2022
SmMIP-tools: a computational toolset for processing and analysis of single-molecule molecular inversion probes-derived data.
Medeiros JJF et al.
Bioinformatics (oxford, England), 2022
Liver Transplantation for Unresectable Intrahepatic Cholangiocarcinoma: The Role of Sequencing Genetic Profiling.
Gruttadauria S et al.
Cancers, 2021
Correlation of molecular data with histopathological and clinical features in a series of 66 patients with medullary thyroid carcinoma.
Moura MM et al.
Journal of Endocrinological Investigation, 2021
Structural bioinformatics enhances mechanistic interpretation of genomic variation, demonstrated through the analyses of 935 distinct RAS family mutations.
Tripathi S et al.
Bioinformatics (oxford, England), 2021
Prognostic Impact of miR-224 and RAS Mutations in Medullary Thyroid Carcinoma.
Cavedon E et al.
International Journal of Endocrinology, 2017
RAS proto-oncogene in medullary thyroid carcinoma.
Moura MM et al.
Endocrine-related Cancer, 2015
Evidence of a low prevalence of RAS mutations in a large medullary thyroid cancer series.
Ciampi R et al.
Thyroid : Official Journal of the American Thyroid Association, 2013
MicroRNA profiles in familial and sporadic medullary thyroid carcinoma: preliminary relationships with RET status and outcome.
Mian C et al.
Thyroid : Official Journal of the American Thyroid Association, 2012
KRAS gene mutations in Noonan syndrome familial cases cluster in the vicinity of the switch II region of the G-domain: report of another family with metopic craniosynostosis.
Brasil AS et al.
American Journal of Medical Genetics. Part A, 2012
Oncogenic activating mutations are associated with local copy gain.
Modrek B et al.
Molecular Cancer Research : Mcr, 2009
A transforming MET mutation discovered in non-small cell lung cancer using microarray-based resequencing.
Tengs T et al.
Cancer Letters, 2006
The mutational spectrum of HRAS, KRAS, NRAS and FGFR3 genes in bladder cancer.
Ouerhani S et al.
Cancer Biomarkers : Section a of Disease Markers, 0